OBD and major European Pharma sign agreement to identify regulatory events underlying the carcinogenic process induced by Non-genotoxic carcinogenesis (NGC).

OBD will use their EpiSwitch™ Discovery Platform to resolve epigenetic knowledge around the carcinogenic process induced by Non-genotoxic carcinogenesis (NGC). The data will be integrated with transcriptional profiling data to mechanistically and functionally characterize this process and develop a new class of potential NGC biomarkers.


OBD and major US Pharma sign agreement to develop epigenetic knowledge and biomarkers to be used in the development of treatments for Lymphoma.

Resolution of the mechanisms that lead to the formation of lymphoma using the EpiSwitch™ Discovery Platform should lead to defined treatments for lymphoma.